Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

PREGNANCY IN SYSTEMIC LUPUS-ERYTHEMATOSUS

PREGNANCY IN SYSTEMIC LUPUS-ERYTHEMATOSUS CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Lockshin, M. D., QAMAR, T., Levy, R. A., Druzin, M. L. 1989; 7: S195-S197

Abstract

Experience with more than 150 pregnancies of women with systemic lupus erythematosus demonstrates that: many conventional measures of lupus activity, including complement, platelet count and urinary protein, are invalid during pregnancy; pregnancy does not cause lupus exacerbation; anti-phospholipid antibody is common and is closely associated with fetal loss, but is not the sole determinant factor of fetal loss; specific characteristics of anti-phospholipid antibody do not identify which antibody-positive women will have poor fetal outcome; prednisone therapy does not improve fetal prognosis; and neonatal lupus, diagnosed by rash and thrombocytopenia, is common but congenital heart block is rare.

View details for Web of Science ID A1989CE25300036

View details for PubMedID 2691157